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EDITORIAL

Measurement of Glomerular Filtration Rate as a
Diagnostic Test: Old Limitations and New
Directions and Challenges Worthy of an Olympic
Gold Medal

M

atthew Emmons, one of the most successful elite
marksman in recent US sports history and a multiple, Olympic medalist, was on track during the Games
of the 28th Olympiad in Athens to win the gold medal in
the “50-m 3-position riﬂe.” Emmons was leading the entire
ﬁeld, points ahead of the next competitor, Jia Zhanbo from
China. First shot ﬁnal round of 9 shots, bull’s eye! Bull’s eye
for the wrong target! With that shot—a crossﬁre—
Emmons lost his chance at a medal. Jia Zhanbo wins the
gold.
Accurate and precise, and given Emmons’ skill, his shot
was likely entirely reproducible, but it gave the wrong
result, it was off target. Had Emmons hit his intended
target, he would have been the gold medalist in his
competition.
Hitting the correct target is akin to obtaining results
from a valid and useful diagnostic test; patients and clinicians win. Diagnostic tests should be like the expert
marksman’s shot. We expect our diagnostic tests to be sufﬁciently reproducible, reliable, and hit the correct target to
facilitate diagnostic precision. Typically, we judge a diagnostic test by how well the test tells us the truth, or how
uncommonly the test yields false positive or false negative
results. We expect these error rates for the diagnostic test
to be low when the diagnostic test results are compared to
the truth, deﬁned by a criterion or gold standard measure
of a particular disease. The true positive rate (proportion
of positives that are correctly identiﬁed) and false negative
rate (1 2 Sensitivity ¼ false negative rate) are reported as
the test’s sensitivity and speciﬁcity (true negative rate).
However, relatively few clinicians have developed an
intrinsic sense of what test sensitivity and speciﬁcity
mean for the interpretation of a test’s results or the management of a patient’s disease.
Of equal or even greater importance, we should expect
that diagnostic tests will not only classify a patient
correctly as having or not having an illness but also provide us with an accurate measure of disease progression

and prognosis with treatment. Importantly, for diseases
such as CKD, we expect that an accurate and reproducible
measure of the stage of CKD will provide us with insights
into the potential impact of CKD along a continuum from
less to more severe disease on the patient’s health status.
The latter is particularly important when clinicians are
evaluating whether a treatment strategy is beneﬁting the
patient and necessitates that the diagnostic test enable
classiﬁcation of subjects into clinically meaningful subsets
according to the severity of their illness and expected
response to treatment.
CKD “staging” is most commonly done using a patient’s
glomerular ﬁltration rate (GFR). It is universally accepted
that an accurate measure of GFR should serve well to classify individuals with CKD. For core diagnostic tests such
as the measurement of GFR in CKD or acute kidney injury
(AKI) patients, 1 property of a diagnostic test is key,
namely the test provides reliable insights into prognosis
with or without speciﬁc treatment(s), so that the result
can fundamentally impact management decisions, patient
choices, and patient-centered outcomes. The diagnostic
test makes a difference for the patient; it has utility.
To fulﬁll these criteria, measurement of GFR ideally
should be reliable, reproducible, and provide an accurate
estimate of GFR independent of disease severity and
should provide consistent information about prognosis
and outcomes. Furthermore, the test should be simple to
perform and interpret and allow for comparisons across
time and between populations. Current methods to measure or estimate GFR fall short of this ideal. The estimations of GFR from serum creatinine or urea while
readily available and generally simple to perform may
be particularly inaccurate at extremes of true GFR where
Ó 2017 by the National Kidney Foundation, Inc. All rights reserved.
1548-5595/$36.00
https://doi.org/10.1053/j.ackd.2017.12.004

Adv Chronic Kidney Dis. 2018;25(1):1-3
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 15, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

1

2

Molony and Yee

an accurate measure of GFR may be particularly important to support clinical decision-making. Examples
include morbidly obese patients, and in certain individuals such as vegans, professional athletes, weightlifters,
and cachectic cancer patients to name a few. Measurement
of intrinsic kidney function in patients undergoing dialysis presents a unique challenge, but accurate measurement of residual intrinsic kidney function has important
treatment, prescription, and outcome implications.
Strategies to address the limitations of the current
methods for measuring GFR are reviewed in the papers
in the current issue of Advances in Chronic Kidney Disease edited by Inker and colleagues. These reviews
describe newer methods that rely on novel biomarkers
and on computer-assisted decision support to develop
and validate complex algorithms generating more accurate estimates of GFR. Olympian Emmons, when addressing in retrospect the failure of his 2004 gold
medal attempt, noted the breakdown of his carefully
practiced system with his failure, in part, attributed to
a paucity of redundancy—he did not identify his target
before he took “the shot.” In a similar vein, a reliance
on a single method to measure GFR fails to address
the limitations inherent in these GFR measures. In this
issue of ACKD, Inker and her colleagues point a way
forward through implementation of recently developed
biomarkers and introduction of redundant systems, all
supported by computer-driven algorithms that are population speciﬁc.
Inker and each of the contributors to this issue of ACKD
clearly acknowledge the challenges ahead and enumerate
speciﬁc aspects of these. A major theme of a number of the
papers is introduced by Inker, Levey, and Coresh who
propose a framework for a more complex methodology
to estimate GFR from a panel of ﬁltration markers, as a
strategy to potentially increase accuracy beyond the conventional estimated GFR or measured GFR determinations. The essential ﬁrst step in addressing the
limitations in the utility of GFR measurements is to validate reliable measures that provide accurate determinations of GFR across all levels of function, in obese and
nonobese individuals, in the very young and the very
old, in cancer patients, in patients on dialysis, in Asian
populations and others, to determine prognosis, identiﬁcation of AKI on CKD, and/or for drug dosing. The chapters in this issue of ACKD address the measurement of
GFR in each of these speciﬁc populations and largely
acknowledge the limitations inherent in selecting the
“gold standard” for validation of these proposed GFR
estimation strategies.
Once the properties of the new GFR measurement are
described and “validated” with evidence from crosssectional observational studies comparing the new GFR
measures to the criterion or gold standard, the second
stage of GFR measurement development commences.
This second stage is the validation of the GFR measurement in terms of how well the measurement predicts clinical outcomes. The full utility of the newer GFR measures
can only be appreciated with such data. This aspect of the
development of strategies to measure GFR while essential

is much more difﬁcult. At a minimum, one requires longitudinal cohort studies to evaluate long-term prognosis
and outcomes. Ideally, the utility of the newer strategies
could be studied using a randomized clinical trial design.
With a randomized controlled trial one might ask; “Are
patient’s “better off” with regard to some important
patient-centered outcomes due to implementation of the
new test. If so, which patients or populations attain the
greatest beneﬁt, and what is the magnitude of this
beneﬁt?” Afterward, prospective, clinical trials can
explore implementation of the test, deﬁned by principles
of “choosing wisely,” and deﬁne to whom and when
and how often such measures of GFR should be employed
in routine clinical practice.
Most of the authors in this issue of ACKD conclude their
reviews with an acknowledgment of the need for a ﬁnal
validation of the GFR measurements that they have
described with prospective clinical trials. Inker and her
colleagues have shown us where to start this journey by
ﬁrst describing the evidence of the limitations of our current measures and then proposing new measures to overcome these limitations. Collectively, the authors in this
issue of ACKD describe the outlines of better GFR measures for diverse populations and a strategy to develop
and test these GFR measures.
Clearly, there is still much work to be done. Some of this
work may seem far aﬁeld, but they may soon become
available strategies that warrant more widespread use
that determine kidney prognosis. A test based on ultrasound technology, shock wave elastography, may inform
practitioners of kidney ﬁbrosis.1 The technique, such as
hepatic ﬁbroscans, determines kidney stiffness and correlates with histological ﬁbrosis.2 If tissue artifact interferences can be mitigated, this method may be
generalizable to common-day practice. Assessment of individuals’ single-nephron glomerular ﬁltration rates
(SNGFRs) may prove informative in the future.3 This sophisticated computed tomography methodology independently correlated greater SNGFRs with disease.
Individuals with higher-than-normal SNGFRs demonstrated relative nephromegaly, more glomerulosclerosis,
and arteriosclerosis by morphometric and stereologic analyses of 1388 biopsies of human kidney transplant donors. Finally, kidney blood oxygen–level dependent
magnetic resonance is a novel imaging tool that detects
changes in tissue oxygenation.4 This methodology, developed to identify those individuals who may beneﬁt from
kidney artery stenosis intervention, has shown promise.
The technique requires computational expertise more
than newer MR equipment, and the preponderance of
data has been generated at the Mayo Clinic, Rochester,
MN. Further validation studies will be required before
this noninvasive technique can be extended for the determination of CKD severity.
After his 1 loss in 2004, Matthew Emmons learned from
his mistake. He developed and tested new competition
strategies and went on to win Olympic medals in 3 Olympiads. The personal rewards were substantial. It is likely
that developing better predictive GFR measures will also
have large rewards for better patient care, better patient
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counseling, and better patient choices. It would be
prudent to invest the nation’s resources required for such
studies.
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